

Supplementary Table S5

Cumulative risk of recurrence and overall survival of patients with HCC according to KIRs, KIR ligands, and compound KIR-HLA genotypes

	Total patients N = 170				HCV related patients N = 97			
	Cumulative risk of recurrence		Overall survival		Cumulative risk of recurrence		Overall survival	
	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)
KIR2DS1	0.940	N.A.	0.698	N.A.	0.760	N.A.	0.369	N.A.
KIR2DS2	0.103	N.A.	0.735	N.A.	0.302	N.A.	0.647	N.A.
KIR2DS3	0.413	N.A.	0.627	N.A.	0.452	N.A.	0.211	N.A.
KIR2DS4	0.249	N.A.	0.851	N.A.	0.833	N.A.	0.456	N.A.
KIR2DS5	0.636	N.A.	0.699	N.A.	0.990	N.A.	0.926	N.A.
HLA-C1	0.793	N.A.	0.283	N.A.	0.694	N.A.	0.105	N.A.
HLA-C2	0.113	N.A.	0.754	N.A.	0.189	N.A.	0.964	N.A.
KIR3DS1+Bw4 80I	0.807	N.A.	0.411	N.A.	0.967	N.A.	0.547	N.A.
KIR3DS1+Bw4 80T	0.749	N.A.	0.666	N.A.	0.428	N.A.	0.873	N.A.

N.A.: not assessed